Pitango HealthTech

Pitango HealthTech is the dedicated healthcare arm of Pitango Venture Capital, the largest and one of the most established venture firms in Israel. The healthtech vehicle leads rounds across digital therapeutics, AI-enabled clinical workflow platforms, and medical devices, drawing on the broader Pitango platform’s depth in software, deep tech, and growth-stage execution. For physician founders building anything that touches the clinical workflow, Pitango HealthTech is one of the more serious lead-investor options in the region.

The stated thesis is wide but consistently clinical. Pitango HealthTech funds companies that change how care is delivered, measured, or paid for, with a particular comfort for software-and-data plays that improve outcomes or efficiency at the bedside. Tytocare and K Health are two of the well-known portfolio companies, and they illustrate the pattern: data-rich, consumer-and-clinician facing platforms with global ambition built out of Israel. The fund leans into companies that can credibly attack the United States market, which means physician founders need a clear United States commercialization story even if early validation is in Israel or Europe.

Check sizes sit in the 5 million to 25 million dollar band and span Series A through Series C, with the fund typically leading or co-leading rounds. Geography is anchored in Israel but global in deployment, with active United States and European exposure. Pre-seed and pure seed founders should look elsewhere first; Pitango HealthTech wants to see clinical evidence, regulatory clarity, and an emerging commercial motion before the term sheet conversation.

The team is built around partners with operating histories in healthcare and software, supported by the broader Pitango platform’s analyst and growth capabilities. Diligence is rigorous and clinically literate, which is an advantage rather than a tax for serious founders.

Approach Pitango HealthTech when your company has at least a Series A profile: clinical validation, an early commercial wedge, regulatory pathway clarity, and a credible answer to the United States question. Warm introductions from Israeli operator networks, United States health-system executives, or co-investors in the broader Pitango orbit are the most reliable path in. Avoid pitching consumer-wellness or unregulated lifestyle plays; the fund is built for clinically integrated companies. Time the conversation when you have six months of runway, a real round forming, and a clear thesis on why you are the right team to win the category globally.